Recruiting OBSERVATIONAL NCT07422337
A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab (BOOSTER)
Blinatumomab's Outcome On Serologic Titers and Efficacy of Revaccination
Sponsor: Arkansas Children's Hospital Research Institute
Conditions
B-Cell ALL B-Cell Acute Lymphoblastic Leukaemia B-Cell Lymphoblastic Leukemia B-Cell Lymphoblastic Leukemia/Lymphoma B-cell Acute Lymphoblastic Leukemia B-cell Acute Lymphoblastic Leukemia (B-ALL) B-cell Childhood Acute Lymphoblastic Leukemia B-cell Leukemia
Updated 1 time since 2026 Last updated: Feb 23, 2026 Started: Jan 13, 2026 Primary completion: Jan 31, 2028 Completion: Jan 31, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A observational or N/A phase clinical study on B-Cell ALL and B-Cell Acute Lymphoblastic Leukaemia, this trial is actively recruiting participants. The trial is conducted by Arkansas Children's Hospital Research Institute and has accumulated 1 data snapshot since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
1 version recorded Recruiting
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Arkansas Children's Hospital Research Institute
- Columbia University
Data source: Arkansas Children's Hospital Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .